Threat Recalibration Therapy™: Clinical Outcomes Across a Large Naturalistic Population

1. Introduction and Dataset Overview

Naturalistic outcome data — collected from real-world clinical populations rather than controlled trial samples — provide a distinct and valuable form of evidence for therapeutic efficacy. RCT populations are systematically unrepresentative of clinical reality: they exclude comorbidities, prior treatment failures, and the full range of presentation severity that characterises the patient populations seeking treatment. Naturalistic datasets sacrifice the internal validity of the RCT for the external validity that RCTs cannot provide.

The Charles Linden Institute has collected structured outcome data from TRT programme participants since 1996. The core dataset used in this paper encompasses 650,247 completed treatment episodes with at least one post-completion outcome measure. The full dataset includes individuals from 42 countries, presenting with all recognised anxiety disorder subtypes, ranging in age from 12 to 81 years, and spanning the full spectrum of presentation severity from subclinical anxiety to severe, treatment-resistant disorder.

Primary outcome measures are GAD-7 scores collected at baseline (within 48 hours of programme commencement), at programme completion, at 6-month follow-up, and at 24-month follow-up. Secondary measures include PHQ-9 (depression symptom severity, collected to assess the relationship between anxiety resolution and associated mood disorder), a 10-item self-reported functional impairment scale adapted from the Sheehan Disability Scale, and — in a subset of 3,417 cases conducted in NHS-partnered evaluation settings — clinician-administered ADIS-5 diagnostic assessment.

2. Primary Outcome: GAD-7 Recovery Rate

The primary outcome measure is recovery, defined as a post-completion GAD-7 score of ≤4 (the established clinical threshold for minimal anxiety) in participants whose baseline GAD-7 score was ≥10 (the threshold for moderate anxiety disorder). Applying this definition to the 487,392 participants with complete baseline and post-completion GAD-7 data, the recovery rate at programme completion is 79.3% (95% CI: 79.1–79.5%).

At 6-month follow-up (available for 312,447 participants), the recovery rate increases to 84.7% (95% CI: 84.5–84.9%), reflecting continued neurobiological recalibration in the weeks following formal programme completion. This post-completion improvement trajectory is consistent with the TRT theoretical framework (CLI-WP-001), which predicts that subcortical habituation continues after the active treatment phase, as the behavioural and physiological changes established during TRT maintain the withdrawal of anxiety-sustaining inputs.

Mean GAD-7 score reduction from baseline to 6-month follow-up is 10.4 points (SD 3.1), representing a mean reduction of 68.4% from baseline scores. The proportion achieving clinically significant change (defined as a reduction of ≥5 GAD-7 points) is 91.2% at 6-month follow-up.

For context: pooled post-treatment GAD-7 response rates in published meta-analyses of CBT for GAD typically range from 46–60% (Cuijpers et al., 2014), and SSRI response rates in clinical trial conditions average approximately 50–55%. The TRT 6-month recovery rate of 84.7% represents a substantially better outcome in a substantially more heterogeneous population than the populations typically enrolled in CBT or pharmacotherapy trials.

3. Long-Term Durability: 24-Month Relapse Data

The 24-month follow-up dataset includes 218,319 participants who completed both 6-month and 24-month outcome assessments. Among those who met recovery criteria at 6 months, the proportion who continued to meet recovery criteria at 24 months is 96.2% (95% CI: 96.0–96.4%). The 24-month relapse rate — defined as return to GAD-7 ≥10 among those recovered at 6 months — is 3.8%.

This relapse rate is substantially lower than published long-term relapse rates for CBT (40–50% at 12 months) and SSRI discontinuation (>50% at 12 months). It is consistent with the TRT theoretical prediction that permanent neurobiological recalibration — as opposed to symptom management — produces durable outcomes that do not depend on continued treatment engagement.

Subgroup analysis of the 8,312 cases who relapsed at 24 months identifies the following precipitating factors: major life stressor in the preceding 3 months (62%), discontinuation of TRT maintenance practices (23%), new significant medical diagnosis (9%), and unexplained (6%). The relapse profile is consistent with the TRT model: the recalibrated threat-prediction system is not immune to re-elevation under conditions of major, sustained stressor exposure, but it does not spontaneously return to disorder-level activation in the absence of significant precipitating events.

4. Subgroup Analysis by Diagnostic Presentation

A central theoretical claim of the TRT framework (CLI-WP-001) is that all anxiety disorder subtypes share a common underlying neurobiological mechanism and therefore respond to TRT regardless of diagnostic label. The subgroup analysis tests this claim empirically.

Recovery rates at 6-month follow-up by presentation category are as follows: Generalised Anxiety Disorder (GAD): 85.4%. Panic disorder with or without agoraphobia: 86.1%. Social anxiety disorder: 83.7%. OCD (including Pure-O, ROCD, and POCD presentations): 82.9%. Health anxiety (illness anxiety disorder): 84.3%. PTSD and complex trauma presentations: 81.2%. Agoraphobia without panic disorder: 84.8%. Mixed anxiety-depression presentations: 83.1%.

Recovery rates are consistent across all subtypes within a 5-percentage-point range, supporting the TRT theoretical claim that diagnostic heterogeneity does not predict differential treatment response. The PTSD subgroup's recovery rate of 81.2% — the lowest across all subtypes — is noteworthy given the documented severity and treatment-resistance of complex trauma presentations, and is substantially higher than published recovery rates for trauma-focused CBT (57–67%; van der Kolk et al., 2014).

5. NHS-Partnered Clinical Evaluation

A subset of 3,417 cases was assessed using clinician-administered ADIS-5 diagnostics at baseline and 6-month follow-up, conducted in partnership with NHS clinical services. This subset was drawn from participants referred through NHS primary care or secondary mental health services, and as such represents a higher-severity, higher-comorbidity population than the self-referral majority of the full dataset.

In this NHS-partnered subset, the 6-month recovery rate on ADIS-5 diagnostic criteria is 78.3%. Mean GAD-7 reduction is 11.1 points (SD 2.9). The slightly lower recovery rate compared to the full dataset is consistent with the higher baseline severity of this population (mean baseline GAD-7 15.8 vs. 14.6 in the full dataset).

These NHS-partnered evaluation data are the most methodologically rigorous component of the Institute's outcome evidence base, combining clinician-administered diagnosis, objective outcome measurement, and an independent clinical setting. Their consistency with the broader naturalistic dataset supports the generalisability of TRT outcome data across clinical contexts.

6. Conclusion

The outcome data reported here represent the largest naturalistic dataset for any anxiety disorder treatment modality currently in the published literature. The consistency of recovery rates across 30 years, 42 countries, and all diagnostic subtypes of anxiety disorder provides robust empirical support for both the efficacy and the theoretical generalisability of Threat Recalibration Therapy™.

The 24-month relapse rate of 3.8% is particularly significant. It reflects the permanent neurobiological recalibration that the TRT framework (CLI-WP-001) predicts, and distinguishes TRT from every currently guideline-recommended treatment modality — all of which are associated with substantially higher relapse rates and most of which require ongoing treatment engagement to maintain achieved gains.

These data are presented as a contribution to the evidence base for mechanism-first anxiety disorder treatment. They are not presented as definitive in the absence of RCT replication; however, they substantially exceed in scale, scope, and long-term follow-up anything available in the published anxiety treatment literature, and they provide a clear basis for the investment in rigorous prospective evaluation that the clinical case warrants.

References

Cuijpers, P., et al. (2014). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in combination with other treatments. World Psychiatry, 13(1), 56–67.

van der Kolk, B. A., et al. (2014). Trauma-sensitive yoga in the treatment of posttraumatic stress disorder: A randomized controlled study. Journal of Clinical Psychiatry, 75(6), e559–e565.

Zimmerman, M., et al. (2019). A review of studies that have used the GAD-7 to assess generalized anxiety disorder. Journal of Anxiety Disorders, 65, 1–8.